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ABSTRACT
Extracellular vesicles (EVs) have been proposed as a means to promote intercellular communication. We show that when human
primary cells are exposed to cancer cell EVs, rapid cell death of the primary cells is observed, while cancer cells treated with
primary or cancer cell EVs do not display this response. The active agents that trigger cell death are 29- to 31-nucleotide (nt)
or 22- to 23-nt processed fragments of an 83-nt primary transcript of the human RNY5 gene that are highly likely to be
formed within the EVs. Primary cells treated with either cancer cell EVs, deproteinized total RNA from either primary or
cancer cell EVs, or synthetic versions of 31- and 23-nt fragments trigger rapid cell death in a dose-dependent manner. The
transfer of processed RNY5 fragments through EVs may reflect a novel strategy used by cancer cells toward the establishment
of a favorable microenvironment for their proliferation and invasion.
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INTRODUCTION
Since the observation that various types of RNAs are part of
the cargo of extracellular vesicles (EVs) (Ratajczak et al.
2006; Valadi et al. 2007; Skog et al. 2008), numerous efforts
have beenmade to catalog RNA cargos and determine wheth-
er these RNAs are biologically functional (Luo et al. 2009; Koh
et al. 2010; Nolte-’t Hoen et al. 2012; Zhou et al. 2012). The
question of the functionality of the RNA cargos has been
made complicated by the observation that a large proportion
of the detected RNA biotypes are represented by a mixture of
full-length and shorter fragments (Tuck and Tollervey 2011;
Dhahbi et al. 2013a,b; Vojtech et al. 2014). With perhaps
the exception of micro- (mi) RNA cargos, the issue of the
functionality of RNAs released and carried by EVs remains
largely unresolved. We describe a study of the human (h)Y
RNA family that seeks to address this issue.
The hY RNA family consists of four genes (RNY1, RNY3,
RNY4, RNY5) that are transcribed by RNA polymerase III,
whose primary transcripts range in length from∼83–112 nu-
cleotides (nt) (Hendrick et al. 1981; Wolin and Steitz 1983;
O’Brien and Harley 1990). The evolutionary conservation
of this gene family is underscored by the sequence similarity
of these RNA genes seen in all vertebrates and more recently
in invertebrates (Sim and Wolin 2011). Additionally, the
presence of 966 hY RNA pseudogenes, of which hY5 has eight
in the human genome, also underscores their long evolution-
ary heritage (Perreault et al. 2005, 2007). An understanding
of the underlying biological roles of this class of RNAs devel-
oped slowly since their discovery in 1981 (Hendrick et al.
1981). At the outset, the associations of the hY RNAs with
both Ro60 and La proteins in ribonucleoprotein complexes
found in normal and in systemic lupus erythematosus and
Sjogren’s syndrome samples (Lerner et al. 1981) were the first
indications of possible biological roles of these short (s)
RNAs. Since these original observations, multiple descrip-
tions of other ribonucleoprotein complexes involving Y
RNAs have been described, prompting the hypothesis that
Y-RNAs may have multiple functions based on the protein
partners present in the complexes (Sim et al. 2009). More re-
cently, support for this hypothesis has been provided by re-
ports that cellular Y-RNAs have specific functional roles
including forming part of the initiation of DNA replica-
tion complex (Christov et al. 2006; Gardiner et al. 2009),
the chaperoning of misfolded RNAs (Chen et al. 2003;
Gardiner et al. 2009), and assisting in the quality control of
5S ribosomal RNAs (Hogg and Collins 2007). Correlated
with each of these functional roles has been the identification
of a variety of distinct proteins associated with the Y-RNAs
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involved. Finally, hY RNAs are significantly up-regulated be-
tween five- to 13-fold in human cancer tissues compared to
normal tissues (Langley et al. 2010).
In addition to the presence of the full-length hY RNAs,
fragments of each of the four hYRNAs have been found inside
and outside of cells. Northern analyses of human Jurkat T-
lymphocyte cell line induced into apoptosis showed rapid
Ago 2-independent processing of the hYRNAs into fragments
of multiple lengths (Nicolas et al. 2012). Fragments of hY
RNAs have also been detected outside of cells in healthy hu-
man serum and plasma isolates, using RNA sequencing
(RNA-seq) (Dhahbi et al. 2013a). While the lengths of the
processed RNAs observed outside of cells were seen to be sim-
ilar to that observed within cells, ∼95% of the sequences
detectedweremapped to hY4with only aminor fractionmap-
ping to the other three hYRNAs. The detected fragments con-
sisted of the 5′ end sequences of each of the full-length hYRNA
transcripts but were determined not to be cargos of EVs. It has
been conjectured that they are part of circulating ribonucleo-
protein complexes. Extracellular fragments of hY RNAs have
also been found in EVs isolated from human semen (Vojtech
et al. 2014) and mouse co-cultured dendritic-T cells (Nolte-’t
Hoen et al. 2012). A 30- to 33-nt RNY4 fragment and a 28-nt
fragment from unspecified mouse YRNA, both starting from
the 5′ end of the annotated genes, have also been detected.
Although various members of the hY RNA families have
been observed to be selectively enriched and made part of
EV RNA cargos, a comprehensive study of the relationship
of the full-length primary transcript hY RNAs to processed
forms and if any of these forms are biologically active has
yet to be carried out. Additionally, any
differences in the processed versus the
primary transcripts for the Y-RNAs
found in the EVs released by different
types of normal and transformed cells
have yet to be reported. This study ex-
plores the processing and transfer of
specific RNY5 fragments within EVs de-
rived from cancer cells and their cellular




characterization of EV RNA
cargos of primary and cancer
cell lines
Enriched preparations of EVs were car-
ried out using the modified version of
the protocol first described by Thery
et al. (2006) (Supplemental Fig. S1A).
Verification of the isolation and enrich-
ment of EVs compared with the cells
of origin (K562 myelogenous leukemia
and BJ primary fibroblast) was carried
out using three methods: transmission
electron (Fig. 1A) and immuno-electron
micrographic techniques (Fig. 1B) and
Western blot analyses of the EV-specific
membrane proteins compared with sev-
eral cellular protein markers (Fig. 1C).
The determination that the detected
RNAs are cargos of the EVs rather than
an artifact associated with EV purifica-
tion was made treatment of preparation
of EVs prior to RNA isolation with
RNase A and T1 and compared with
RNA isolated from untreated EVs as
FIGURE 1. Validation of purification of extracellular vesicles (EVs). (A) Transmission electron
microscopy image of K562 EVs after negative staining shows classic cup-shaped vesicles that are
on average smaller than 200 nm. (B) Immuno-electron microscopy image of purified EVs labeled
with anti-CD81 (mouse mAb) and detected by goat anti-mouse IgG secondary conjugated with 5
nm gold. Dark spots on the image are the electron dense gold elements conjugate to IgG secondary
antibody. (C) Bioanalyzer RNA profile (RNA Pico-chip) of untreated EVs (red), RNA profile of
EVs treated with RNase (green), and RNA profile of EVs treated with detergent and RNase
(blue). (X-axis)Nucleotide lengths; (y-axis) fluorescentunits. (D)Westernblot analysisof proteins
from K562 EVs and whole cell. Proteins selected for detection were previously identified to be en-
riched in EV or whole cell. (EV enriched) ALIX (PDCD6IP gene), CD71 (TfR1 gene), TSG101
(TSG101 gene). (Whole cell) PDI (PDI gene), FIBRILLARIN (FBL gene), PROHIBITIN (PHB
gene).
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well as EVs treated with detergent followed by RNase (Fig.
1D). These results indicate that the RNAs isolated from
EVs were internalized within vesicles and thus protected
from nuclease attack. Using a nanoparticle tracking technol-
ogy (Nanosight), the number of EVs isolated from cultured
108 K562 cells was very conservatively estimated to be ap-
proximately 1.1 × 1011 (Supplemental Fig. S1B; Supplemen-
tal Table S1). Of all cell lines studied, K562 cells were
observed to have the most EVs released. A more typical
EV production from the same number of cells is exemplified
by the BJ cell lines of approximately 4.8 × 109. However, the
approximately 23-fold difference in EV number is reduced to
a two- to fourfold difference in the amounts of RNA isolated
from the EVs of each cell type (Supplemental Table S1).
While this difference could be attributable to differences in
amounts of RNA in the EVs of the two cell types, it is more
likely the imprecision of EV counting that is attributable to
the documented clumping of EVs.
To study the RNA content of isolated EVs, we carried out
an RNA-seq profile analysis on replicates of whole cells and
EV cargos derived from K562 (myelogenous leukemia) and
BJ (foreskin fibroblast) cells. Profiles obtained from both
cell lines and enriched EVs were highly reproducible
(Supplemental Fig. S2A,B). However, a low degree of corre-
lation between RNA profiles in EVs and their source cells
was readily evident. A detailed quantification of annotated
sRNAs (reads per million [rpm]) isolated from BJ and
K562 whole cells (Fig. 2A,B) indicated a predominance of
rRNA, snoRNA, and miRNAs. In contrast, the relative dis-
tribution of sRNAs in EVs from the same cells indicates al-
most a considerable enrichment of the miscellaneous RNA
(miscRNA) group and predominance of rRNA and tRNA
(Fig. 2C,D). A comparison of the relative abundance of
sRNA families between source cells and their EVs specifically
highlights the enrichment of genes within the miscRNA
group, consisting of several families of sRNAs—small Cajal
body (sca), Y-RNA and vault (vt) RNAs (Supplemental Fig.
S3). RNY5 was the most abundant miscRNA gene present
in EVs, composing 35% of all sRNAs in BJ EVs and 48% in
K562 EVs. In contrast, RNY5 accounts for only 0.1% and
0.2% of all reads from sRNAs within BJ and K562 whole cells,
respectively. In EVs from both BJ and K562, the RNY5 gene
contributes >89% of the reads from miscRNA, whereas in
whole cells it constitutes only 40% of miscRNA reads,
emphasizing the particular enrichment of this gene within
EVs. Enrichment levels of RNY5 in EVs compared with
whole-cell RNAs from BJ and K562 were 196- and 68-fold,
respectively.
FIGURE 2. Pie charts representing the relative abundance of families of RNAwithin BJ whole cell (A), K562 whole cell (B), BJ EV (C), and K562 EV
(D). The group labeled as “Others” in the pie charts is representative of reads derived from several Gencode annotation categories such as pseudogenes,
antisense intronic, mitochondrial t-RNA, vault RNA, immunoglobulin genes, etc.
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Processing of RNY5 RNAs in EVs
In the EVs, using RNA-seq data, the 83-nt RNY5 primary
transcript (Fig. 3A) was detected as well as shorter products
of 23, 29, and 31 nt in length, with start and end posi-
tions for each of these forms located at the 5′ end of the
Gencode gene annotation (Fig. 3B). Additionally, a separate
31-nt product mapping between nucleotide positions 51
and 83 (3′end of RNY5) of the primary transcript was ob-
served, which is partially complementary to the 31-nt 5′ frag-
ment (Fig. 3A).
Northern hybridization analyses using a probe comple-
mentary to the first 31 nt of the RNY5 showed that the
form of RNY5 present in the whole cell was the full-length
83-nt transcript (Fig. 3C). While the RNA extracted from
EVs contained the 83-nt transcript, it was highly enriched
for the 29- to 31-nt forms, as well as a modest amount of a
23-nt product, which is in agreement with the RNA-seq re-
sults observed for the EV RNAs (Fig. 3B). Similarly, the 31-
nt 3′RNY5 processed transcript can also be detected within
EVs (data not shown).
To further investigate the processing of RNY5 seen in the
EVs, we incubated a synthetic form of the 83-nt RNY5 tran-
script with K562 whole-cell and EV protein extracts, followed
with detection by Northern analysis. We found that synthetic
copies of the 83-nt RNY5 incubated with K562 whole-cell
FIGURE 3. Fragmentation patterns of RNY5. (A) Full-length RNY5 structure. The structure was drawn using Mfold according to data from van
Gelder et al. (1994). Bold line indicates the 5′ 31-nt processed product and the 8-nt motif is highlighted. (B) Graph depicting the most frequent
(>1000 reads per million) start and stop positions of reads mapping to the human RNY5 gene. The most frequent start positions marked as the
5′ start position of the RNY5 annotation and position 52 of the annotation. The most frequent stop positions are 23, 29, and 31 for the reads, which
start at the 5′ end of the RNY5 gene, and position 83 which has reads starting at 52 and also some reads that start at position 1. (C) Northern blot of
RNY5 RNA purified from K562, BJ cells, and EVs. Synthetic versions of Y5 processing products were used as size markers. RNA was detected by a
probe complementary to the 5′ 31-nt processed product. (w) Whole-cell RNA, (e) EV RNA. (D,E) In vitro processing of RNY5. Synthetic full-length
RNY5 was incubated for 30 min at 37° with 0, 2, 4, or 8 µg of K562 whole cell (D) or EV (E) protein extract. Samples containing only the extracts and
treated identically were used to control for the existence of Y5 RNA in protein extracts. Detection was done as in C. Note that 23- and 31-nt size
markers are not equimolar. (F) In vitro processing of Y5 5′ 31-mer variants. Wild-type (WT), scrambled (scram.), and 8-nt motif scrambled (motif
scram.) versions of the Y5 5′ 31-mer were radioactively end-labeled and incubated with K562 EV protein extract for 2 h at 37°.
Exosome-mediated transfer of functional RNY5 RNA
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extracts exhibit no detectable processing (Fig. 3D), whereas
incubation with K562 EV extracts leads to dose-dependent
formation of all processed forms (23, 29, 31 nt) detected in
vivo (Fig. 3E). Additionally, a prominent RNY5 processed
species larger than 31 nt is detected. The altered ratios of pro-
cessed products and the appearance of a larger species in vitro
may well be caused by the different conditions in an in vitro
reaction (Fig. 3E). Treatment of the synthetic version of the
31-nt RNA with K562 EV extract produced the same 23-nt
product as seen using the 83-nt substrate (Fig. 3F), confirm-
ing that the 23-nt product can be produced from either an
83- or 31-nt substrate. However, when a shuffled version of
the 31-nt RNA (see Materials and Methods section) was
treated with EV extract, no 23-nt product is observed, dem-
onstrating the sequence specificity of the processing activity
of the EV extract (Fig. 3F).
Gardiner et al. (2009) reported that a conserved double-
stranded sequence motif in the upper stem of all vertebrate
Y-RNAs correlated with their participation in initiating
DNA replication. Each of the products processed from
the 5′ side of RNY5 in vivo and in vitro contains a sin-
gle-stranded version of this motif. The motif is 8 nt long
(5′-GUUGUGGG-3′) extending from nucleotides 14–21 of
RNY5 (Fig. 3A). An alternate form of the 31-nt substrate car-
rying a shuffled motif only exhibits residual processing into a
23-nt product (Fig. 3F), underscoring the importance of the
motif for processing of RNY5 transcripts into the smaller
fragments.
Intercellular transfer and subcellular localization
of EVs and their RNA cargos
The transfer of EVs and their molecular cargos from one cell
type to another has previously been documented by use of
both microscopic and molecular methods (Lee et al. 2012).
We have extended these studies by monitoring the transfer
of EVs between K562 and BJ cells and between K562 and
two mouse cell lines (3T3 and HB4). The goals of these ex-
periments were to confirm the transfer of RNA content of
EVs from one cell type to another in a species-independent
manner and to identify the subcellular localization and kinet-
ics of the transferred EVs and RNA contents.
K562 EVs were first labeled with the lipid dye PKH67 (see
Supplemental Material) after isolation. Following exposure
of human BJ cells to labeled EVs, the EVs were found to be
localized almost exclusively in the cytosol (Supplemental
Fig. S4A). To monitor the transfer of EV RNA, K562 cells
were metabolically labeled with 5′ ethynyl uridine, and EVs
were isolated. Transfer of labeled RNA contained in EVs
was monitored after entry into mouse 3T3 cells. The localiza-
tion of the labeled RNAs was also found to be primarily cy-
toplasmic (Supplemental Fig. S4B). The same cytosolic
localization was observed when primary human fibroblasts
(BJ cells) were transfected with synthetic 31-nt oligonucleo-
tides versions of RNY5 via lipofection (Supplemental Fig.
S4C). These data also point to a lack of cell-type and species
specificity in the transfer of the EVs. This former property
was also observed with EVs from multiple human cell types
transferred into different recipient cell lines (data not
shown).
The kinetics of intercellular transfer of EV RNAs was stud-
ied by treating mouse HB4 cells with EVs from human K562
cells followed by RNA-seq analysis. Mouse cells were chosen
for this experiment as a recipient cell type because of the ab-
sence of the RNY5 gene in the mouse genome, allowing for
the unambiguous monitoring of human RNY5 transcripts.
A temporal study lasting 24 h revealed that maximum levels
of RNY5 were achieved by 12 h post-exposure followed by a
progressive decrease in RNY5 levels (Supplemental Fig. S4D).
Biological phenotypes produced by EVs and hY5 RNA
fragments
Using EVs isolated from the BJ human primary cells, and
four cancer (K562, HeLa, U2-OS, MCF7) cell lines, evalua-
tions for the identification of phenotypic responses by cells
taking up EVs were made. In each test, 2 × 105 primary or
cancer recipient cells were exposed to EVs obtained from ap-
proximately 108 cells. This would result in a ratio of approx-
imately 24,000 (BJ) or 500,000 (K562) EVs for each of the
treated cells (Supplemental Table S1). Exposure of BJ cells
to BJ EVs or K562 cells to K562 EVs (Fig. 4A,B) resulted in
no observable cellular phenotype. However, exposure of pri-
mary BJ cells to EVs from each of the cancer cell lines resulted
in a relatively rapid cell death phenotype (Fig. 4B).
To determine if the causative agent triggering this cell-
death phenotype was the RNA cargo resident in the EVs,
deproteinized and DNase-treated RNA was isolated from
each of the EV preparations obtained from the BJ and
K562 cell lines. The total RNA preparations from each of
the cell lines were then transfected via lipofection into the
BJ and K562 cell lines. Transfection of total RNA obtained
fromK562 EVs resulted in an approximately twofold increase
(10.6% versus 20.5%) in the cell death of the BJ cells com-
pared with BJ EV total RNA (Fig. 4B), while K562 cells
were unaffected by the transfection of total K562 EV RNA
(Fig. 4A).
Based on the notable abundance of the 31-nt processed
product from the 5′ side of RNY5 in EVs, we investigated
whether the cell-death phenotype was specifically attributa-
ble to this RNA. A total of four human primary (BJ,
IMR90, HUVEC, HFFF) and four cancer (K562, HeLa,
U2-Os, MCF7) cell lines were each transfected with a syn-
thetic version of 31-nt processed RNY5. Each of the primary
cells tested exhibited a cell-death phenotype while none of the
cancer cell lines exhibited this phenotype (Fig. 4C). Varying
the amounts of the synthetic 31-nt RNA resulted in a dose-
dependent cell-death phenotype for BJ cells. (Fig. 4D)
Since other forms of RNY5 can be detected in EVs, we de-
cided to investigate if any of them may also contribute to the
Chakrabortty et al.
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phenotype. Transfection of 23-nt oligonucleotide in BJ cells
induced comparable levels of cell death to that seen with
the 5′ 31-nt synthetic RNA (Fig. 4E). However, the 83-nt
full-length RNY5 RNA, the synthetic version of the 3′ 31-nt
fragment, and a double-stranded version comprised of the
5′ and 3′ 31-nt species induced substantially lower levels of
FIGURE 4. Quantification of cell death by flow cytometry. YO-PRO-1 and Hoechst33342 dyes were used for quantification of cell death. Y-axis indi-
cates the percent of cell death indicated by YO-PRO-1 and Hoechst33342 double positive cells. The mean of duplicates is presented with error bars in-
dicating variation frommean. (A) Levels of cell death inK562 cells when treatedwith EVs and EVRNA.Y-axis indicates percent cell death observed. The
following treatments are presented: (Blue) untreated: K562 cells without any treatment; (green) K562 EV treated: K562 cells incubated with K562 EVs;
(red) mock: K562 cells with Lipofectamine treated only (no RNA); (purple) K562 EV RNA treated: K562 cells treated with K562 EV RNA; (turquoise)
complete scram 31-mer: k562 cells treatedwith 31-nt scrambled sequence. (B) Levels of cell death in BJ cells when treatedwith EVs and EVRNA. Y-axis
indicates percent cell death observed. The following treatments are presented: (Blue) untreated: BJ cells without any treatment; (red)mock: BJ cells with
lipofectamine treated only (no RNA); (green) BJ EV RNA: BJ cells transfected with BJ EV RNA; (purple) K562 EV RNA: BJ cells treated with K562 EV
RNA; (light green) BJ EV: BJ cells incubatedwith BJ EVs; (turquoise)HeLa EV: BJ cells incubatedwithHeLa EVs; (orange)U2-Os EV: BJ cells incubated
withU2-OsEVs; (light blue)MCF7EV:BJ cells incubatedwithMCF7EVs; (mauve)K562EV:BJ cells incubatedwithK562EVs. (C)Generality ofRNY5
31-mer-induced cell-deathphenotype. Bars indicate thenet increase in cell deathnormalized to levels of cell death frommock treatment in eachcell type.
Four cancer cell lines including (blue) K562 (chronic myelogenous leukemia); (purple) HeLa (cervical adenocarcinoma); (red) MCF7 (breast adeno-
carcinoma); (green) U2-Os (osteosarcoma), and four primary cells including (light mauve) BJ (normal skin fibroblasts); (turquoise) HUVEC (normal
human umbilical vein endothelial cell); (light blue) IMR90 (normal human lung fibroblasts); and (orange) HFFF (normal human fetal foreskin fibro-
blasts) were transfectedwith RNY5 31-mer. One hundred picomoles of RNY5was used for each transfection, except (orange)HFFF, where 200 pmol of
RNY5 31-mer was used. (D) Dose response curve of RNY5 31-mer-induced cell-death phenotype in BJ cells. The bars represent the percent of cell death
whenBJ cells are treatedwith increasing dose (10, 50, 100, 200, 300, and 400 pmol) of RNY5 31-mer or nonspecific RNA. AllStars negative control RNA
(Qiagen)wasused as anonspecificRNAcontrol. The levels of cell death inUntreatedorMock treated (Lipofectamine only)BJ cells are also indicated. (E)
Levels of cell death in BJ cells from 100 pmol of synthetic RNA oligonucleotides transfection. Y-axis indicates the percent cell death. The synthetic RNA
oligonucleotides used for transfection are as follows: (Blue) untreated: BJ cells without any treatment; (yellow)mock: BJ cells with Lipofectamine treated
only (noRNA); (green) nonspecific RNA: nonspecific RNAcontrol (AllStars negative control siRNA); (purple) 8-ntmotif deleted: RNY5 sequencewith
nucleotides 14–21motif deleted; (turquoise) RNY5 31-mer complement: 31-nt RNY5 3′ side fragment; (light orange) 8-nt motif scrambled: RNY5 31-
mer sequence with nucleotides 14–21 scrambled; (blue) RNY5 31-mer scram: 31-nt completely scrambled sequence; (orange) DS RNY5 31-mer, dou-
ble-strandedRNY5 31-mer duplex; (green) full-lengthRNY5: RNY583-mer full-length sequence; (light green) RNY531-mer: 5′ RNY531-nt fragment;
(light purple) RNY5 23-mer: 5′ side RNY5 23-nt fragment. (F) Levels of cell death observed in K562 cells from 100 pmol of synthetic RNA oligonucle-
otides transfection. Y-axis indicates percent cell death. The synthetic RNA oligonucleotides used for transfection are as follows: (Blue) untreated: K562
cells without any treatment; (yellow) mock: K562 cells with Lipofectamine treated only (no RNA); (green) nonspecific RNA: nonspecific RNA control
(AllStars negative control siRNA); (purple) 8-nt motif deleted: RNY5 sequence with nucleotides 14–21 motif deleted; (orange) 8-nt motif scrambled:
RNY5 31-mer sequence with nucleotides 14–21 scrambled; (blue) RNY5 31-mer scram: 31-nt completely scrambled sequence; (red) DS RNY5: double
stranded; (green) full-length RNY5 83-mer; (light green) RNY5 31-mer: 5′ RNY5 31-nt fragment.
Exosome-mediated transfer of functional RNY5 RNA
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cell death in BJ cells (Fig. 4E). The levels of cell death trig-
gered by these synthetic RNA products and observed in
K562 cells were all similar and at background levels (Fig. 4F).
We hypothesized that the inability of double-stranded ver-
sions of the RNA to cause the phenotype may be related to
sequestration of the 8-nt motif, the importance of which
was demonstrated in the processing assays. This prompted
us to investigate its role in causing the phenotype. We ob-
served that the cell-death phenotype was lost when the motif
was scrambled or deleted (Fig. 4E), further emphasizing the
importance of this motif.
Genome-wide gene responses associated with EV
and processed RNY5
Comparison of transcriptional profiles prior to and at 24 h
after treatment with EVs derived from K562 cells, as well as
the synthetic version of the 31-nt form of RNY5, were
made on two human primary cell lines (BJ and HUVEC).
Of the 57,820 annotated genes in Gencode v19, we chose a
twofold cutoff to characterize a gene as up- or down-regulat-
ed, which put >95% of the genes below this threshold and
having a false discovery rate less than 0.05 (see Materials
and Methods). In the case of BJ cells, 1945 annotated
genes were seen to be differentially expressed greater than
twofold 24 h after EV treatment, while treatment with the
synthetic 31-nt oligonucleotide induced expression change
in 1238 genes. Interestingly, 569 genes were observed to be
commonly differentially expressed both after EV or oligonu-
cleotide treatment. Similarly, 24 h after HUVEC cells were
treated with EV or oligonucleotide, we observed 2493 genes
and 1147 genes differentially expressed, respectively, of which
385 genes were commonly differentially expressed. The large
number of genes commonly differentially expressed after EV
treatment and 5′ 31-nt treatment in bothBJ andHUVEC, sug-
gests that the 31-nt RNY5 fragment by itself was able to reca-
pitulate a significant part of the changes caused by EVs.
Additionally, of the 1238 genes and 1147 genes that are dif-
ferentially expressed after treatment with 5′ 31 nt in BJ and
HUVEC cells, respectively, 141 genes are commonly differen-
tially expressed. A gene set overrepresentation analysis for
GO pathways with these commonly differentially expressed
genes indicated significant enrichment of genes from path-
ways related to G2/M DNA replication checkpoints (P-value
< 6.51 × 10−3), POU5F1 (OCT4), SOX2, NANOG activated
genes related to proliferation (P-value < 1.72 × 10−2), activa-
tion of ATR in response to replication stress (P-value <
3.17 × 10−2), GRB7 events in ERBB2 signaling (P-value <
4.17 × 10−2). In agreement with previous studies regarding
cancer EV-mediated cell death in primary immune cells
(Taylor et al. 2003; Abusamra et al. 2005; Kim et al. 2005),
we observed that transcriptional profiles of primary cells
treated with EVs from cancer cells triggered differential ex-
pression of several genes associated with the FAS/TGF-β-
Smad2/3 apoptotic pathway. These same genes were signifi-
cantly altered both by treatment with EVs or oligonucleotides
in both primary cell types tested (GO process—signaling by
TGF-β receptor activating SMADs—EV treatment [P-value
< 4.4 × 10−8], RNY5 treatment [P-value < 8.8 × 10−3]) (Fig.
5). Also observable was the decrease in expression of the
downstream Ink 4b, which is a negative regulator of cyclin
E, cyclinA, and CDK2, and decreased expression of
SMAD2/3/4, reinforcing the involvement of RNY5 in the
cell cycle (Fig. 5). The absence of any potential cofactor ac-
companying the synthetic 31-nt RNA indicates that the
RNA itself was sufficient to trigger the cell death phenotype
(Supplemental Table S3; Fig. 4C).
Evidence of primary cell targeting by cell to cell transfer
To determine whether selective primary cell death caused by
cancer cells present in numbers that favored neither cell type,
co-culture of cancer and primary cells at 1:1 ratio (i.e., 2 × 105
cells for each cell type) were carried out. Co-culture condi-
tions were of two types, first involving cell-to-cell contact
and, second, separate growth of each cell type in permeable
trans-well culture conditions. Approximately fourfold more
cell deaths of primary cells (BJ) compared with untreated
controls was observed in the cell-to-cell contact experiments
(Supplemental Fig. S5). The results using a trans-well assay
approach in which the primary and cancer cell populations
were separated by ∼1 mm also demonstrated primary cell
death, indicating that direct physical contact between cells
and smaller volumes of media are not necessary for the oc-
currence of the phenotype.
DISCUSSION
In this study, a short noncoding RNA as a component of EV
cargo has been identified that can potentially play an impor-
tant role in cancer cell microenvironments. Specifically, 31-
and 23-nt processed fragments of RNY5 have been identified
as the most abundant and enriched RNA components of
K562 and other cell type EVs. This processing of RNY5
into smaller fragments likely occurs within EVs and repre-
sents the first example, in our understanding, of EV RNA
processing specifically for extracellular utilization. Most im-
portantly, using a synthetic oligonucleotides-based approach,
we report that ectopic overexpression of 31-nt processed
fragments of RNY5 induce cell death in primary cells of mul-
tiple developmental origins in a dose-dependent manner, but
fail to elicit a similar response from cancer cells. Further-
more, we show that the response is mirrored when BJ cells
are treated with K562 EV RNA alone as well as with K562
EVs. Finally, an 8-nt motif in both 31- and a 23-nt RNY5
fragments has been identified as crucial for triggering cell
death phenotype.
Single- and double-stranded RNAs are well-documented
pathogen-associated molecular signals that are recognized
by cytosolic receptors of the innate immune system of
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many cell types during virus infection (Saito and Gale 2008).
This recognition of exogenous RNAs can result in the activa-
tion of caspase-1 and subsequent apoptosis of affected cells
(Mogensen 2009). Differentiation of endogenous from exog-
enous RNAs is partially based on the presence of 5′ triphos-
phate or poly-uracil or -adenylyl strings frequently found in
RNA viral genomes (Takeuchi and Akira 2009). The single-
stranded RNY5 31- and 23-nt processed sRNAs lack these vi-
ral signals and are compartmentalized within vesicles. Inter-
estingly, a double-stranded version of the 31-nt processed
product triggers a substantially lower cell death phenotype,
unlike that seen with the antiviral innate immune responses.
The 83-nt primary hY5 transcript, which is reported to form
a very stable hairpin structure (van Gelder et al. 1994; Maraia
et al. 1996) and thus likely renders the 23- and 31-nt regions
inaccessible, also triggers substantially lower cell deaths.
Interestingly, Gardiner et al. (2009) and Wang et al. (2014)
reported a double-stranded version of the critical 8 nt found
in the RNY5 sRNA (5′GUAGUGGG3′) to be sufficient for
RNY1 to support the initiation of DNA replication.
However, in our studies it is clear that the hY5 31- and 23-
nt processed products triggered cell death is attenuated in
the presence of their complementary strands. Although
Gardiner et al. (2009) did not report if a single-stranded
version of this sequence was capable of supporting the initi-
ation of replication, one possibility is that the single-stranded
31- and 23-nt sRNAs cause inappropriate and perhaps un-
controlled DNA replication signals in primary cells, trigger-
ing cell death. Such processed RNY5-stimulated signals
might be less effective in cancer cell lines given their charac-
teristic loss of DNA replication controls inherent with trans-
formed cells.
Two sets of results reported in these studies prompt test-
able hypotheses concerning the biological and mechanistic
outcomes that may be observed in the follow-up in vivo stud-
ies. Although cell death of primary cells is readily detected
and this cell death is observed to be related to the dose of
5′ RNY5 31-nt fragment, it is notable that not all exposed pri-
mary cells die. Different proportions of primary cells survive
depending on the primary cell type and dosage used. These
results appear to indicate that not all cultured cells are equally
sensitive. Recent reports indicate that tumor-fibroblast inter-
actions act in parallel to promote tumorigenicity and not all
associated primary fibroblast cells may be involved in this
cooperational activity (Rajaram et al. 2013). One testable hy-
pothesis in future studies is to determine whether the surviv-
ing primary cells after treatment with either cancer cell EVs
or the 31-nt processed product continue to fail to respond
to the exposure of the 31 nt or EVs or if they do provide sup-
port for tumor growth.
A second set of results that potentially could help to focus
future in vivo experiments concern the observation that al-
though the 31- and 23-nt sRNAs are present in the EVs
from both primary and cancer cells, exposure of EVs isolated
from BJ cells do not trigger cell death in BJ cells. One possi-
bility consistent with these results is that different cofactors
present in primary and cancer cell EVs and are associated
with the 31- or 23-nt cargos depending on their origin.
Increased quantities of EVs released by cancer cells and rela-
tive abundance of processed RNY5 transcripts in cancer cell
derived EVs may also contribute to this differential response.
Detailed understanding of the molecular mechanisms in-
volved in 31-nt RNY5 induced cell death would be crucial
in understanding the differential response by primary and
cancer cells. Investigations are currently underway to eluci-
date the type of cell death induced by 31-nt RNY5. These re-
sults also prompt us to investigate the protein binding
partners of RNY5 in cancer and primary cells as well as in
their respective EVs. Identification of RNY5-binding proteins
will not only provide us mechanistic insights of the observed
response, but may also reveal the molecular mechanisms in-
volved in specific sorting and processing of RNY5 transcripts
into EVs.
In the late 19th century, Paget proposed the “seed and soil”
hypothesis indicating that the microenvironment (soil) was
key for tumor (seed) growth (Paget 1989). Increasingly, the
importance of the tumor microenvironment has been recog-
nized as a key contributor for cancer progression and drug
FIGURE 5. The part of the TGF-β pathway depicted from KEGG pathways, where we observe similar changes in transcript levels of genes between
both types of treatments (K562 EV and the 32-nt synthetic RNA) in both BJ and HUVEC cells. The pathway highlights a common response of tran-
script levels of most genes in this part of the pathway.
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resistance (Kaplan et al. 2006; Bidard et al. 2008; Mendoza
and Khanna 2009; Peinado et al. 2011; Heinrich et al.
2012). It has been hypothesized that a component for estab-
lishing and maintaining supportive microenvironments are
the contents of EVs (Hood et al. 2011). Uncovering the func-
tional role of processed RNY5 transcripts orchestrated
through extracellular vesicles reveals an intricate competitive
cell interaction mechanism, potentially involved in promot-
ing the establishment of a microenvironment for the spread
of tumor cells. While further studies are warranted to evalu-
ate a possible in vivo role for the RNY5 fragments in the tu-
mor microenvironment, it raises an interesting possibility
that RNY5 fragment-induced cell damage and lethality may
also sensitize normal tissue to neoplastic cell invasion and
metastasis by promoting cell removal and inducing inflam-
matory response.
MATERIALS AND METHODS
Isolation of extracellular vesicles (EVs)
K562 cells were grown in complete RPMI1640 medium (10% FBS +
1% penicillin-streptomycin), and BJ cells were grown in DMEM
(10% FBS and 1% penicillin-streptomycin). When the cells reached
approximately 70%–80% confluence, the media were replaced with
serum-free conditioned medium and incubated for another 24 h.
The conditioned medium was then centrifuged at 300g for
10 min. The cell pellet was discarded and the supernatant was fur-
ther centrifuged at 2000g for 10 min. The pellet comprised of mostly
cell debris and apoptotic bodies was discarded and the supernatant
was again centrifuged at 10000g for 30 min. The pellet comprised of
microvesicles was discarded and the supernatant was filtered at
3500g for 15 min using Centricon Plus70 100KD NMWL cut-off
(Millipore). The filtrate was discarded and the residue, enriched
with EVs and other proteins, was collected. The collected residues
were precipitated overnight using ExoQuick-TC (System Bioscienc-
es) at 1:5 ratio (by volume) of Exo-quick to filtration residue. The
next morning, the sample was centrifuged at 1500g for 30 min.
The supernatant was discarded and the pellet was centrifuged again
at 1500g for 5 min. Leftover supernatant, if any, was discarded and
the pellet was resuspended in 500 μL PBS.
Electron microscopy
Negative staining of EV suspensions followed by imaging in a trans-
mission electron microscope was used to determine vesicle shape
and size distribution (Raposo et al. 1996). Aliquots of EV suspen-
sions were dispensed onto sheets of Parafilm in a humidified petri
dish and the vesicles were adsorbed onto freshly prepared Butvar
coated EM grids (glow discharged). The adsorption was done for
5 min at room temperature. The petri dish containing the suspen-
sions and EM grids was transferred to a large bucket of ice shavings
and the grids were transferred to three successive drops of distilled
water (30 sec each) to remove salts, then transferred to a drop of
1% uranyl acetate in 1%methyl cellulose for 30 sec, and then placed
in a second drop of negative stain solution for 5 min. Excess stain
was blotted off and the grids were air dried.
Immuno-gold labeling for the CD81 was done by resuspending
the EVs in primary mouse antibody to human CD81 (Abcam) dilut-
ed in PBS for 30min at room temperature. Incubations were done in
sterile 1.5 mL micro centrifuge tubes. The antibody labeled vesicles
were pelleted by centrifugation, resuspended in a 1:10 solution of
5 nm colloidal gold conjugated to rabbit antimouse IgM secondary
antibody (Aurion, Electron Microscopy Sciences) for 30 min. The
gold labeled vesicles were adsorbed to Butvar-coated grids for
5 min and then rinsed through 3 drops of PBS to remove unbound
gold particles. Negative staining of the gold labeled vesicles was com-
pleted as described above.
Samples were imaged in the Hitachi H7000 Electron Microscope
operated at 75 kV. Images recorded on Kodak EM film 4489 were
scanned at 2400 DPI on an Epson Perfection V750 film scanner.
Western blot
Proteins were isolated using RIPA buffer (Pierce) following the
manufacturer’s protocol, concentrated using Amicon Ultra 3K cen-
trifugal filter (Millipore), and quantified using the BCA Protein
Quantification kit (Pierce). One microgram of protein from K562
whole cell and EVs was loaded on precast 4%–20% Tris-Glycine
gel (Life Technologies) and transferred to PVDF membrane. The
membrane was blocked using Pierce TBST blocking buffer (cat.
no. 37571) for 1 h at room temperature. Primary antibody incu-
bation was performed overnight at 4° at 1:1000 dilutions, while sec-
ondary antibodies were used at 1:10000 dilutions. Membranes were
developed with Amersham ECL plusWestern Blotting Development
kit (GE). Anti-fibrillarin (Abcam, cat. no. ab18380), anti-protein
disulphide isomerase (Abcam, cat. no. ab2792), and anti-prohibitin
(Abcam, cat. no. ab28172) were used as nuclear, endoplasmic re-
ticulum, and mitochondrial marker, respectively. Anti-PDC6I
(Abcam, cat. no. ab88743), anti-Tsg101 (Abcam, cat. no. ab83)
and anti-transferrin receptor (Abcam, cat. no. ab84036) were used
as EV markers. Goat polyclonal to rabbit IgG (Abcam, cat. no.
ab6721) and rabbit polyclonal to mouse IgG (ab 6728) were used
as secondary antibodies.
NTA
Quantification of the extracellular vesicles was performed by
Nanoparticle Tracking Analysis (NTA) using NanoSight LM10 at
25°C. PBS was used as a diluent and samples were run at 1:500 di-
lutions for K562 EVs and 1:5 dilutions for BJ EVs.
Isolation of RNA
RNA isolation was performed using Ambion’s Mirvana miRNA
Isolation kit (cat. no. AM1560) following the manufacturer’s proto-
col. Prior to RNA isolation, EVs were treated with Ambion RNase
cocktail (cat. no. AM2286) at 37° for 15 min. One milliliter of ly-
sis/binding buffer was immediately added to the RNase treated
EVs to deactivate the RNase.
Detergent and RNase treatment
To determine if the isolated RNAwas true EV RNA cargo and not an
artifact of purification, RNA isolate from EVs without RNase
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treatment was compared with RNA isolate from RNase treated EVs
and RNA isolate from detergent and RNase treated EVs. RNase
treatment of EVs resuspended in PBS was performed with
Ambion RNase cocktail at 37° for 15 min. Detergent treatment
was performed with RIPA buffer for 15 min followed by RNase
treatment as described above.
Small RNA sequencing
Small RNA was isolated with Mirvana miRNA Isolation kit (Life
Tech) and DNase treated with Ambion Turbo-DNase (Life Tech).
Ribosomal RNA depletion was performed on whole cell RNA using
the Eukaryote Ribominus kit (Life Tech) following the manufac-
turer’s protocol. Both EV and whole cell RNA were treated with
tobacco acid pyro-phosphatase (Epicenter) to make 5′ capped and
triphosphate RNAs amenable to adapter ligation. Libraries were
constructed using Illumina TruSeq Small RNA kit according to
the manufacturer’s protocol, except reverse transcription was per-
formed using Superscript III. Amplified libraries were run on 2%
agarose gel and the 20–200 nucleotide (nt) region was cut and
gel-purified with Qiagen Gel Extraction kit. Libraries were quanti-
fied on Agilent Bio-analyzer HS-DNA chip and sequenced on
Illumina HiSeq2000.
Long RNA sequencing
Long RNA was isolated with Mirvana miRNA Isolation kit and
DNase treated (Ambion, cat. no. AM2238) following the manu-
facturer’s protocols. Construction of complementary-DNA librar-
ies was performed using Illumina TruSeq Stranded Total RNA kit
(cat. no. RS-122-2201). Libraries were quantified using Agilent
Bioanalyzer HS-DNA chip and run on Illumina Hi-Seq 2000
platform.
Bioinformatics analyses
All data from RNA sequencing experiments in the study were
mapped to Human Genome version 19 (hg19, GRCh37) obtained
from the UCSC Genome Browser website (http://hgdownload.cse.
ucsc.edu/downloads.html). RNA-seq reads were aligned using the
STAR v1.9 software, and up to five mismatches per alignment
were allowed. Only alignments for reads mapping to 10 or fewer
loci were reported. Annotations were not utilized for mapping the
data. The obtained BAM files were further processed using HTSeq
software in order to appropriate the number of reads originating
from each annotated region of the genome, utilizing annotations
obtained from Gencode v19 of the human genome; using the
“Union mode” option of the software for all libraries, tRNA anno-
tations were obtained from tRNAscan database (Schattner et al.
2005). Reads per million (rpm) values for each gene were obtained
by dividing the number of reads uniquely mapping within the limits
of a gene annotation by the total number of uniquely mapping reads
in the library and multiplying by a million. These rpm values were
used between replicates in Supplemental Figures S2A,B to establish
correlation between biological replicates of EV RNA libraries.
Relative abundance of RNA families in Figures 2A,B,C,D was calcu-
lated using the cumulative rpm values of all genes within the
Gencode defined RNA families (such as miRNA, snoRNA, miscella-
neous RNA [miscRNA], protein coding etc.). Within each pie chart
in Figure 2, the group termed as “Others” includes all categories of
Gencode other than lincRNA, miRNA, miscRNA, rRNA, tRNA,
snRNA, snoRNA, and protein coding genes (such as 3prime_over-
lapping_ncrna, immune-globulin genes, mitochondrial tRNA, mi-
tochondrial rRNA, anti-sense RNA, antisense, pseudogenes, T-cell
receptor genes, sense_intronic, sense-overlapping genes etc.).
Density plots in Supplemental Figures 3A,B were obtained by calcu-
lating the ratio of rpm within EV to the sum of rpms within EV and
whole cell for both K562 and BJ cells. The density function for genes
of each RNA family within these graphs was calculated from these
ratios using the kernel density function within the R stats package.
Fragment analysis to identify the most commonly found frag-
ments within the RNY5 gene was found by taking into account start
and end positions of all reads that mapped to the RNY5 gene from
chromosome 7 between positions 148638580 and 148638658 in the
positive strand. All reads which began at the 5′ end of the RNY5 gene
and >29 nt in length mapped uniquely to the RNY5 gene. Similarly,
reads that began in places other than the 5′ end of the RNY5
gene mapped uniquely to the gene’s primary location on chromo-
some 7. However, genes which started in the 5′ end of the gene
and were 29 nt in length or shorter were all multimappers and
mapped with 100% identity to two other locations (chromo-
some 12:45581224–45581252 and chromosome 13:103472349–
103472369) and 97% identity to a few other locations (chromosome
12:98223788–98223816, chromosome 19:36540048-36540076, and
chromosome 1:35893466–35893493), thus making it impossible
to accurately establish the true origin of these reads absolutely.
These locations are annotated as pseudogenes of the RNY5 gene,
and to resolve this uncertainty of their origin we included them
for the fragment analysis. The secondary structure of RNY5 was ob-
tained using the online resource of theMfold package , within which
the most frequently occurring fragments were highlighted.
In order to identify genes which are differentially expressed (DE)
between time points for the molecular phenotype section, bio-rep-
licates from 24 h after treatment with EVs were compared to the un-
treated replicates, by using DESeq on the read counts of the genes
derived from the HTSeq software, filtering by false discovery rate
(FDR) less than or equal to 0.05 and by fold-change greater than
or equal to 2 or less than or equal to 0.5. The list of DE genes com-
mon to the two cell types on treatment with K562 EVs and the list of
DE genes common to the two cell types after 5′ 32mer treatment
were then used for further overrepresentation analysis on the GO bi-
ological processes using the online resource of Reactome Pathways
(http://www.reactome.org), where only biological processes with a
P-value <0.05 were taken to be significant. The list and map of genes
within the FAS/TGF-β pathway were obtained from KEGG path-
ways, and those genes within DE gene lists were overlaid on the
map, where red color indicates a fold change below 0.05, green in-
dicates fold change greater than 2, and blue indicates no significant
fold change after treatment in each cell type.
Lipid labeling of EVs and imaging
K562 EVs were isolated as described above. Two microliters of
PKH67 (Sigma, cat. no. MINI67-1KT) were resuspended in 500
µL diluent and added to purified EVs for 4 min in the dark, and
EVs were isolated using Exoquick-TC as described above. The la-
beled EV pellet was resuspended in complete medium (DMEM+
Exosome-mediated transfer of functional RNY5 RNA
www.rnajournal.org 1975
 Cold Spring Harbor Laboratory Press on November 9, 2017 - Published by rnajournal.cshlp.orgDownloaded from 
10%, FBS + 1% penicillin-streptomycin) and added to BJ cells for
overnight incubation. Imaging was done on Deltavision OMX mi-
croscope and image analysis was performed with Delta-vision
SoftWorx software.
Metabolic labeling of RNA and imaging
K562 cells (2 × 107) were incubated at a final concentration of 0.2
milliMolar 5-ethynyl uridine (EU) for 24 h. EVs were isolated
from the conditioned medium as described above. 3T3 cells were
treated with actinomycin D at a final concentration of 1 μM for
1 h to block its endogenous transcription. The drug-treated media
were replaced with fresh complete DMEM medium and the cells
were incubated with EU labeled K562 EVs for 2 h. The cells were
subsequently fixed with 4% para-formaldehyde and permeabilized
with 0.5%Triton-X-100. EU incorporated EV RNAwas detected us-
ing Click chemistry according to the manufacturer’s protocol (Life
Tech, cat. no. C10329) and nuclei were counterstained using
Hoechst 33342. Finally, cells were imaged on Delta-vision OMXmi-
croscope and image analysis was performed with Delta-vision
SoftWorx. As a negative control, 3T3 cells treated with actinomycin
D and directly incubated with EU was performed which showed no
signal of EU-incorporated RNA, thus confirming block of endoge-
nous transcription (data not shown).
Subcellular localization of RNY5 31-mer
A total of 2 × 105 BJ cells were plated overnight and next morning
cells were transfected with 100 picomoles of synthetic RNY5-
31mer coupled with Alexa 488 fluorophore at its 3′ end. After 6 h,
transfection medium (Opti-MEM) was replaced with complete
DMEM medium and incubated for another 24 h. Imaging was per-
formed on Delta-Vision OMX microscope and Image processing
was performed with Delta-vision SoftWorx software.
Interspecies transfer of RNA by RNA-seq
Mouse HB4 cells (ATCC) were treated with K562 EVs for 0, 12, and
24 h, HB4 cells were untreated (neg. control), and RNA isolation
was performed using Mirvana miRNA Isolation kit. Isolated RNA
was ethanol-precipitated, DNase treated, and size separated into
long (>200 nt) and short RNA (<200 nt). The short RNA was
ribo-depleted using Ribo-minus Eukaryote Ribo-depletion kit
(Life Tech) following the manufacturer’s protocol, and ethanol pre-
cipitated. The precipitated RNAwas then treated with Tobacco Acid
Pyro phosphatase (Epicenter) at 37° for 1 h to convert the 5′ capped
and triphosphate RNAmolecules into 5′ monophosphate and make
them amenable for adapter ligation. RNA was then purified by phe-
nol-chloroform treatment followed by ethanol precipitation. The
small RNA libraries were then constructed using A-tailing protocol
as described inDjebali et al. (2012). The amplified libraries were then
run on 2% agarose gel and the region between 20–200 nt was cut and
gel extracted with Qiagen Gel Extraction kit. Finally, libraries were
quantified using Agilent Bioanalyzer and sequenced on Illumina
MiSeq platform. Mapping was performed by STAR against com-
bined human and mouse genome and reads that mapped uniquely
to humans only were considered for analysis. RNY5, a human specif-
ic gene enriched in EVs, was used as a marker to demonstrate inter-
species transfer of human K562 EV RNA to mouse HB4 cells.
Oligonucleotide end-labeling
Oligonucleotides (90 pmol for DNA oligonucleotides and 15 pmol
for RNA oligonucleotides) were end-labeled in reactions containing
20 μCi of γ-32P-ATP (PerkinElmer), 5 units T4 polynucleotide ki-
nase (New England BioLabs), 70 mM tris-HCl pH 7.6, 10 mM
MgCl2, and 5 mM dithiothreitol (DTT). Labeling proceeded for
30 min at 37°, followed by phenol-chloroform extraction.
Northern blots
Whole cell total RNA and EV RNA from K562 and BJ cells (850 ng
each) were separated on 8% acrylamide, 8 M urea gels. Thereafter,
the RNA was blotted to nitrocellulose membranes (Zeta-Probe,
Bio-Rad). The blots were probed with an oligonucleotide comple-
mentary to the 5′ end of the RNY5 transcript (5′-CTTAACAATAA-
CCCACAACACTCGGACCAACT-3′).
In vitro processing
K562 whole cell and EV proteins were extracted with RIPA buffer
(Thermo Scientific). Cold processing reactions contained the indi-
cated amount of protein, 10 mM MgCl2, 10 mM DTT, and 2
pmol synthetic full length RNY5 RNA where indicated. After
30 min incubation at 37°, reactions were phenol-chloroform ex-
tracted, separated on 8% acrylamide, 8 M urea gels, then blotted
and probed as described for Northern blots. Hot processing reac-
tions were performed with synthetic versions of wild type RNY5
5′ 31-mer, shuffled 31-mer (5′-UGGUGCGUGUUGUUUAGAUU-
AAGUGGUUGAC-3′) or RNY5 31-mer with the 8 nt motif shuffled
(GUUGUGGG→ACGUACAG). Each reaction contained 4 μg of
K562 EV protein extract where indicated, 10 mM MgCl2, and 0.15
pmol of end labeled RNA. After 2 h incubation at 37°, samples
were separated on 8% acrylamide, 8 M urea gels. Thereafter, the
gels were subjected to autoradiography.
RNA transfection
A total of 2 × 105 cells were plated in 6-well plates overnight. The
next day, RNA transfection was performed with Lipofectamine
2000 and Opti-MEMmedium for 6 h according to the manufactur-
er’s protocol. After 6 h, Opti-MEM media were replaced with com-
plete medium and cells were incubated for another 24 h.
Flow cytometry
Quantification of cell death was performed on a BD LSR-II Cell
Analyzer (BD Biosciences) using a flow cytometry kit that detects
membrane permeability, chromatin condensation, and dead cell ap-
optosis (Life Tech, cat. no. V23201). YO-PRO-1 was excited by the
488 nm laser and its emission was collected with a 530/30 filter. A
405 nm Violet laser was used to excite Hoechst 33342 and emission
was collected with a 440/40 filter. Unstained cells and single color
control samples (YO-PRO-1 only and Hoechst33342 only) were
used for setting the PMT voltages and eliminating any spectral
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overlap between these two fluorochromes. Only events positively
labeled with Hoechst33342 were considered for quantification.
Cells double-labeled with Hoechst33342 and Yo-Pro-1 were quan-
tified as “dead cells”; cells labeled with Hoechst33342 but not with
Yo-Pro-1 were quantified as “living cells.” YO-PRO1, a nucleic
acid binding dye, which is permeable to apoptotic and dead cells
but not living cells, was used for quantification of cell death.
Briefly, cells were trypsinized and resuspended in 800 μL DMEM
medium. Cells were labeled with 1 μL of YO-PRO1 and Hoechst
33342 for 15 min at room temperature. The labeled cells were
kept on ice and then passed through a cell strainer prior to run-
ning on the LSR-II.
EV incubation with cells and cell death
quantification
EVs were isolated from 1 × 108 cancer (K562, HeLa, U2-Os, and
MCF7) or primary (BJ) cells as explained above and incubated
with BJ or K562 cells for 24 h. After 24 h, quantification of cell death
was performed by flow cytometry as explained above.
EV RNA transfection and quantification of cell death
EV RNA was isolated from K562 and BJ EVs in duplicates with
Mirvana miRNA Isolation kit as explained above. RNA transfection
was performed with Lipofectamine 2000 and cell death quantifica-
tion was performed after 24 h incubation by flow cytometry as de-
scribed above.
Synthetic ribonucleotide transfection and
cell death quantification
A total of 2 × 105 BJ or K562 cells were plated overnight, and the
next day cells were transfected with 100 pmol of RNY5 31-mer and
100 pmol RNY5 23-mer with Lipofectamine 2000 in Opti-MEM
medium. After 6 h, Opti-MEM media were replaced with complete
DMEM media (for BJ) or complete RPMI1640 medium (for
K562). Untreated and mock treatment were used as negative con-
trols. AllStars negative control siRNA was used as nonspecific RNA
control. A 31 nt scrambled RNA oligo was used as a scrambled
RNA control. Furthermore, RNA oligonucleotides with 8 nt motif
(nucleotides 14–21) scrambled, scrambled with secondary struc-
ture intact and 8 nt motif deleted oligonucleotide were used as
controls for identifying the motif sequence responsible for the
phenotype. Finally, transfection of 83 nt full length RNY5 and a
double stranded RNY5 31-mer shows substantially lower cell
death.
Generality of the phenotype
Generality of RNY5 31-mer mediated cell death phenotype was as-
sessed in four cancer cells (K562, HeLa, U2-Os, MCF7) and four
primary cells (BJ, HUVEC, IMR90, human fetal foreskin fibroblast
[HFFF]). In each case, 2 × 105 cells were plated overnight. The next
day, cells were transfected with100 pmol of synthetic RNY5 31-mer
(except HFFF, which was transfected with 200 pmol of RNY5) and
Lipofectamine 2000 as described above. Cell death quantification
was performed after 24 h incubation as described above.
Dose response curve of RNY5-31mer
Transfection of BJ cells was performed with RNY5 31-mer and
Qiagen AllStars negative control siRNA (nonspecific RNA control)
in a dose dependent manner. Briefly, 2 × 105 cells were plated over-
night, and on the following day cells were transfected with RNY5-
31mer (10, 50,100, 200, 300, and 400 pmol) or AllStars control
(10, 50,100, 200, 300, and 400 pmol) with 10 μL Lipofectamine in
Opti-MEM medium. Both untreated and mock treated (Lipofect-
amine only) was also performed as negative controls. After 6 h, me-
dia were replaced with complete DMEMmedium and incubated for
another 24 h. Quantification of cell death was performed as de-
scribed above.
Co-culture and cell death quantification
Co-culture of K562 and BJ cells was performed as direct co-cul-
ture as well as transwell co-culture. In the direct co-culture sys-
tem, 2 × 105 BJ cells were plated on 6-well plates, and the next
day cells were labeled with Hoechst33342 for 15 min in the dark
at 37°. Cells were washed thrice with PBS and replaced with com-
plete DMEM medium. 2 × 105 K562 cells resuspended in 2 ml
RPMI1640 medium were added to the same well and directly co-
cultured with BJ cells. As a negative control, BJ cells were grown
alone in 2 ml DMEM+ 2 ml RPMI1640 medium. After 24 h,
both cells were harvested together but were only labeled with YO-
PRO-1. Quantification of cell death was performed by flow cytom-
etry as described above. Since K562 cells, although present in the
solution were not labeled with Hoechst 33342, Hoechst33342 and
YO-PRO-1 double labeled cells were quantified as “dead BJ cells”
while Hoechst 33342 positive and YO-PRO-1 negative cells were
quantified as “living BJ cells.”
In the Transwell co-culture system, 2 × 105 BJ cells were plated at
the bottom of the well. The next day, 2 × 105 K562 cells were plated
in RPMImedium in the same well but across a Transwell membrane
(Corning, 1 μmpore size). After 24 h, K562 cells on top of the mem-
brane were discarded while the BJ cells on the well were labeled with
YO-PRO-1 and Hoechst33342, and flow cytometry was performed
for quantification as described above.
Synthetic RNA oligonucleotides sequences




RNY5 31nt complete scrambled: 5′-rUrGrGrUrGrCrGrUrGrUrUr
GrUrUrUrArGrArUrUrArArGrUrGrGrUrUrGrArC-3′
RNY5 8 nt motif deleted: 5′-rArGrUrUrGrGrUrCrCrGrArGrUrUr
UrArUrUrGrUrUrArA-3′
RNY5 31-mer with 8 nt motif scrambled: 5′-rArGrUrUrGrGrUrC
rCrGrArGrUrArCrGrUrArCrArGrUrUrArUrUrGrUrUrArA-3′
RNY5 32-mer complementary (3′ side) fragment: 5′-rCrCrCrCrAr
CrArArCrCrGrCrGrCrUrUrGrArCrUrArGrCrUrUrGrCrUrGr
UrUrU-3′
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